20 results
DEFA14A
CRBU
Caribou Biosciences Inc
11 Aug 22
Additional proxy soliciting materials
4:06pm
, strengthening our team, and achieving corporate milestones that, ultimately, help us advance our mission to develop innovative, transformative therapies … of experience and valuable public company expertise to advise and drive innovation as we execute on our mission. Caribou’s board of directors now
8-K
EX-99.2
CRBU
Caribou Biosciences Inc
10 Jun 22
Regulation FD Disclosure
7:54am
H. Essell, MD
Aiming to set a new therapeutic bar for patients Our mission is to develop innovative, transformative therapies for patients … Diego Moores Cancer Center, La Jolla Additional sites coming soon THANK YOU for your contributions toward Caribou’s mission to develop innovative
8-K
EX-99.2
CRBU
Caribou Biosciences Inc
12 May 22
Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19
10:03am
to execute on our mission 1 As of February 23, 2022 data cutoff date, data collection ongoing, efficacy based on Lugano criteria 2 $391M in cash, cash … mission to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing
Q&A
See you at EHA in June
8-K
EX-99.1
CRBU
Caribou Biosciences Inc
18 Jan 22
Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer
8:02am
, and regulatory authorities to achieve Caribou’s mission to provide innovative, transformative therapies for patients with devastating diseases.”
Dr. Rizvi most
8-K
EX-99.2
CRBU
Caribou Biosciences Inc
13 Jul 23
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
4:23pm
Hospital, Columbus Additional sites coming soon THANK YOU for your contributions toward Caribou’s mission to develop innovative, transformative therapies … toward Caribou’s mission to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing
24 CB-010
8-K
EX-99.1
a3nep71mpcu9f79qvi
8 Jan 24
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8:00am
8-K
EX-99.1
w9f3e
11 Mar 24
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:22pm
ARS
tb8978c mnfp
25 Apr 24
Annual report to shareholders
4:06pm
DRS
EX-10.1
b83no z6n
7 May 21
Draft registration statement
12:00am
DRS/A
EX-10.1
yms91bevg195ra8u6mq
11 Jun 21
Draft registration statement (amended)
12:00am
S-1
EX-10.1
prnrod twym6qg7d8h
1 Jul 21
IPO registration
4:05pm
S-1
c0synr5j
1 Jul 21
IPO registration
4:05pm
10-K
t8prai59
21 Mar 22
Annual report
4:19pm
DRS
aghyx hvze9udl
7 May 21
Draft registration statement
12:00am
ARS
oxguoiauc
28 Apr 23
Annual report to shareholders
12:00am
S-1/A
d8ujrn5cs mfec
19 Jul 21
IPO registration (amended)
6:09am
424B4
0u1jwnxl
23 Jul 21
Prospectus supplement with pricing info
4:24pm
DRS/A
o4yalyu
11 Jun 21
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next